Aciont® to Present at the 13th Annual NIH SBIR/STTR Conference
Dr. Kongnara Papangkorn’s presentation is entitled, “Safety Aspects and Drug Delivery Performance of Visulex® Passive Delivery System”
Salt Lake City, UT, June 09, 2011 --(PR.com)-- Aciont Inc. announced today that Dr. Kongnara Papangkorn, Research Director, has been selected to present at the 13th Annual NIH SBIR/STTR Conference, June 22-23, 2011 at the Natcher Conference Center in Bethesda, Maryland.
Dr. Papangkorn’s abstract, entitled, “Safety Aspects and Drug Delivery Performance of Visulex® Passive Delivery System,” will take place on June 22, 2011 from 2:45 – 3:45 pm during the poster session on the atrium level of the Conference Center. Over fifty NIH SBIR/STTR Phase II awardees will display their scientific findings during the poster session to over 400 conference attendees. Information about the conference can be found at http://grants.nih.gov/grants/funding/SBIRConf2011/agenda.html.
“We are thankful for the support of the NEI, and are very excited to share our latest results with the agency and other attendees on the NIH campus,” stated Dr. Papangkorn. “Our preclinical data appear to indicate that our DSP Visulex system is safe and performs well in terms of treating a preclinical uveitis model and delivering therapeutically relevant amounts of steroid drug to both the front and back of the eye in a rabbit model,” said Balbir Brar, Ph.D., D.V.M., Aciont’s Vice President of Research and Development. “Much of the data will be used to support our IND filing,” Brar added.
###
Aciont Inc. is a specialty biopharmaceutical company endeavoring to become the world leader in commercializing localized, non-invasive (topical passive diffusion-based and iontophoretic), controlled and sustained release back of the eye therapeutics for sight threatening diseases such as severe uveitis, diabetic macular edema and age-related macular degeneration. Aciont’s goal is to provide ophthalmologists substantially greater freedom in treating and/or preventing chronic eye diseases through optimal drug dosing and improved patient/physician compliance. Aciont is located in Salt Lake City, Utah. For more information, visit the company’s website at www.aciont.com.
Source: Aciont Inc.
Contact
John Higuchi, CEO
Aciont, Inc.
(801) 359-3461
admin@aciont.com
Dr. Papangkorn’s abstract, entitled, “Safety Aspects and Drug Delivery Performance of Visulex® Passive Delivery System,” will take place on June 22, 2011 from 2:45 – 3:45 pm during the poster session on the atrium level of the Conference Center. Over fifty NIH SBIR/STTR Phase II awardees will display their scientific findings during the poster session to over 400 conference attendees. Information about the conference can be found at http://grants.nih.gov/grants/funding/SBIRConf2011/agenda.html.
“We are thankful for the support of the NEI, and are very excited to share our latest results with the agency and other attendees on the NIH campus,” stated Dr. Papangkorn. “Our preclinical data appear to indicate that our DSP Visulex system is safe and performs well in terms of treating a preclinical uveitis model and delivering therapeutically relevant amounts of steroid drug to both the front and back of the eye in a rabbit model,” said Balbir Brar, Ph.D., D.V.M., Aciont’s Vice President of Research and Development. “Much of the data will be used to support our IND filing,” Brar added.
###
Aciont Inc. is a specialty biopharmaceutical company endeavoring to become the world leader in commercializing localized, non-invasive (topical passive diffusion-based and iontophoretic), controlled and sustained release back of the eye therapeutics for sight threatening diseases such as severe uveitis, diabetic macular edema and age-related macular degeneration. Aciont’s goal is to provide ophthalmologists substantially greater freedom in treating and/or preventing chronic eye diseases through optimal drug dosing and improved patient/physician compliance. Aciont is located in Salt Lake City, Utah. For more information, visit the company’s website at www.aciont.com.
Source: Aciont Inc.
Contact
John Higuchi, CEO
Aciont, Inc.
(801) 359-3461
admin@aciont.com
Contact
Aciont Inc
Jillian Conrad
801-359-3461
aciont.com
Jillian Conrad
801-359-3461
aciont.com
Contact
Categories